Login to Your Account



Search

Search results

Pharma: clinic roundup

Glaxosmithkline plc (GSK), of London, said a pivotal phase III study of mepolizumab, an investigational IL-5 antagonist monoclonal antibody, met its primary endpoint of reducing the frequency of exacerbations in patients with severe eosinophilic ast ...

BioWorld Today - Staff - 2014-03-14 00:00 - 0 comments - 0 attachments

Clinic roundup

Senesco Technologies Inc. , of Bridgewater, N.J., opened two sites in the Republic of South Africa in its open-label, multiple-dose, dose-escalation phase Ib/IIa study of SNS01-T, which is evaluating the safety and tolerability in 15 patients wit ...

BioWorld Today - Staff - 2014-03-13 00:00 - 0 comments - 0 attachments

Pharma: clinic roundup

Pfizer Inc. , of New York, reported that detailed results of the Community-Acquired Pneumonia Immunization Trial in Adults, or CAPiTA, which enrolled approximately 85,000 subjects, demonstrated that Prevenar 13 (pneumococcal polysaccharide conjugat ...

BioWorld Today - Staff - 2014-03-13 00:00 - 0 comments - 0 attachments

Clinic roundup

Cytonet GmbH & Co. KG , of Weinheim, Germany, said interim data on its liver cell therapy treatment presented at the Society for Inherited Metabolic Disorders meeting in Pacific Grove, Calif., showed that pediatric patients with urea cycle disord ...

BioWorld Today - Staff - 2014-03-12 00:00 - 0 comments - 0 attachments

Clinic roundup

Betagenon AB and Baltic Bio AB , both of Stockholm, said phase I studies began with O304, an orally available AMPK activator. (BioWorld-Today-2014-03-11) ...

BioWorld Today - Staff - 2014-03-11 00:00 - 0 comments - 0 attachments

Clinic roundup

Northwest Biotherapeutics Inc. , of Bethesda, Md., said the data safety monitoring board has made an unblinded review of the safety data for the company’s ongoing international phase III glioblastoma trial with DCVax-L, using activated dendritic ce ...

BioWorld Today - Staff - 2014-03-10 00:00 - 0 comments - 0 attachments

Pharma: Clinic roundup

Boehringer Ingelheim GmbH , of Ingelheim, Germany, reported results from the phase III STARTVerso 4 trial in patients co-infected with hepatitis C virus (HCV) and HIV, showing that HCV cure 12 weeks (SVR12) after the conclusion of treatment was ach ...

BioWorld Today - Staff - 2014-03-07 01:00 - 0 comments - 0 attachments

Clinic Roundup

Esperion Therapeutics Inc. , of Plymouth, Mich., reported in conjunction with its 2013 year-end results that it plans this month to initiate the ETC-1002-009 phase IIb study of parallel doses of lead compound, ETC-1002, over 12 weeks added to stati ...

BioWorld Today - Staff - 2014-03-07 01:00 - 0 comments - 0 attachments

Clinic roundup

Sangamo Biosciences Inc. , of Richmond, Calif., presented data from all dose cohorts in ongoing clinical trials (SB-728-1101 and SB-728-902 Cohort 5) of SB-728-T, which is being developed for the functional control of HIV/AIDS. (BioWorld-Tod ...

BioWorld Today - Staff - 2013-12-09 01:00 - 0 comments - 0 attachments

Clinic roundup

Ico Therapeutics Inc. , of Vancouver, British Columbia, disclosed the final, eight-month patient visit in the phase II iDEAL study. The investigator-sponsored study is evaluating the efficacy and safety of ICO-007 after repeated injections in pat ...

BioWorld Today - Staff - 2014-03-06 01:00 - 0 comments - 0 attachments